The COVID-19 pandemic forced pharmaceutical research laboratories to do more with less, despite relentless demand for new therapeutic agents. Now, life science researchers and vendors are contemplating how to best guarantee safety and quality as some of these changes become permanent and accelerate transformational initiatives.

Frost & Sullivan, the Growth Pipeline Company™ for almost 60 years, hosted a virtual think tank entitled The Pharmaceutical Research and Development Laboratory of the Future. The purpose of the think tank was to discuss important issues encountered in the past year, explore various needs and changes in the way pharmaceutical R&D is conducted in the laboratory, and deliberate what could be in store for the future.

This summary document highlights important insights, perspectives, and takeaways from the session.